Cronos Group (NASDAQ:CRON) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Cronos Group (NASDAQ:CRON) issued its earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.01, reports. The company had revenue of $58.39 million for the quarter, compared to analyst estimates of $38.51 million. Cronos Group had a net margin of 27.27% and a negative return on equity of 1.12%.

Here are the key takeaways from Cronos Group’s conference call:

• Record 2025 financials — Cronos reported Q4 net revenue of $44.5M (up 47% YoY) and organic full‑year net revenue growth of 25%, with record full‑year gross profit and Adjusted EBITDA, and a strong balance sheet of $832M cash and short‑term investments.
• Canadian brand and product momentum — Spinach led growth (vapes rose to #2 overall and #1 in vape cartridges in Q4), Sours edibles approached ~22% category share, and the new all‑in‑one PUFFERZ vape launched in select provinces with broader rollout planned in early 2026.
• International expansion and Netherlands acquisition — Israel net revenue grew 52% YoY and Cronos agreed to acquire CanAdelaar for €57.5M (~$67.5M) with earnouts, positioning Cronos in the Dutch adult‑use program and expanding its European footprint; management called the deal accretive.
• Near‑term margin and operational headwinds — Q4 adjusted gross margin weakened due to GrowCo expansion production quality mix and expense timing (Adjusted EBITDA was only $0.5M in Q4 and below earlier quarters), though management expects margins to normalize toward a ~43% run rate and CapEx to be modest in 2026.

Cronos Group Stock Down 3.6%

Shares of Cronos Group stock traded down $0.10 during trading hours on Thursday, hitting $2.67. The company’s stock had a trading volume of 2,622,335 shares, compared to its average volume of 1,162,407. The business has a fifty day moving average of $2.65 and a 200 day moving average of $2.60. Cronos Group has a 1-year low of $1.60 and a 1-year high of $3.43. The company has a market capitalization of $1.02 billion, a PE ratio of 26.70 and a beta of 0.80.

Institutional Trading of Cronos Group

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC grew its holdings in Cronos Group by 10.4% during the 4th quarter. Virtu Financial LLC now owns 52,852 shares of the company’s stock worth $139,000 after acquiring an additional 4,990 shares in the last quarter. Pillsbury Lake Capital LLC bought a new stake in Cronos Group in the fourth quarter valued at about $4,837,000. Jump Financial LLC acquired a new stake in Cronos Group during the fourth quarter valued at approximately $42,000. Headlands Technologies LLC lifted its holdings in Cronos Group by 12.5% during the 4th quarter. Headlands Technologies LLC now owns 63,097 shares of the company’s stock worth $166,000 after buying an additional 6,998 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Cronos Group in the 4th quarter valued at approximately $196,000. 8.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CRON shares. Zacks Research downgraded shares of Cronos Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. TD Securities initiated coverage on shares of Cronos Group in a research note on Tuesday. They issued a “buy” rating for the company. Wall Street Zen raised Cronos Group from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “hold (c)” rating on shares of Cronos Group in a report on Monday, December 29th. Finally, Canaccord Genuity Group assumed coverage on Cronos Group in a research report on Tuesday, January 27th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.30.

Trending Headlines about Cronos Group

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q4 earnings beat consensus — Cronos reported $0.02 EPS vs. street $0.01 and outperformed revenue expectations, which supports near-term sentiment and valuation re-rating. MarketBeat Earnings Report
• Positive Sentiment: Top-line growth and strong liquidity — company reported record Q4 net revenue (+47% YoY) and FY revenue growth, with an industry-leading balance sheet (reported ~$832M in cash & short-term investments), which reduces financing risk and funds expansion. GlobeNewswire Press Release
• Positive Sentiment: Analyst/idea coverage highlights growth runway — a recent Seeking Alpha piece notes geographic expansion (Europe, Australia), acquisitions and capacity gains as drivers for margin and revenue improvement over 24–36 months, supporting a bullish case at current valuation. Seeking Alpha Bullish Analysis
• Neutral Sentiment: Short-interest data appears inconsistent/glitched in recent release (reported as zero); no clear signal from short-interest trends to explain intraday moves.
• Negative Sentiment: Foreign-exchange losses drove the quarter to a GAAP loss and produced negative headlines — coverage cites FX swings as the main drag on results, which is likely contributing to downward pressure on the stock despite the operational beats. Seeking Alpha: FX Losses MarketWatch: FX Impact

Cronos Group Company Profile

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.